Understanding how broadly neutralizing antibodies may help HIV cure trials
Official title: Defining broadly neutralizing antibody pharmacokinetics-pharmacodynamics in curative HIV trials
Funded at University of California, San Francisco · NIH-11553282 · Data updated 2026-11-12
A study at UC San Francisco looks at how antibody medicines behave in people on and off HIV therapy to help design better cure strategies.
Quick facts
| Grant type | NIH-funded research |
|---|---|
| Study type | NIH-funded research |
| Funding institution | University of California, San Francisco NIH-funded |
| Lab location | 1 site (San Francisco, United States) |
| Project start | September 11, 2026 |
| Project end | August 31, 2027 |
| Funding year | 2026 |
| Award (this year) | $1,489,546 |
| NIH project number | 1R56AI198100-01A1 |
| Project ID | NIH-11553282 on NIH RePORTER |
Who could benefit from this research
✓Could help
Adults with HIV who are participating in or considering analytic treatment interruption (ATI) in bnAb-based cure trials.
✕Less likely to help
People not undergoing bnAb-based ATI or without scheduled bnAb administration may not benefit from this study.
What this research studies
This project examines how broadly neutralizing antibodies (bnAbs) move through the body and interact with HIV after people stop antiretroviral therapy. Researchers will measure bnAb levels, bnAb-HIV complexes, and responses in blood and tissues using advanced lab techniques and imaging. The goal is to identify dosing that keeps the virus in check without exhausting the immune response, guiding future cure trials. It is designed to map how individual differences affect bnAb effectiveness and to optimize treatment interruption strategies.
Why it matters
Potential benefit: If successful, the work could improve bnAb dosing to sustain viral control in future HIV cure trials, potentially shortening infection-related risks during treatment interruptions.
How similar studies have gone: Previous work with bnAbs in HIV has shown promise but dosing and tissue exposure remain open questions; this study seeks to clarify those aspects.
Where this research is happening
-
University of California, San Francisco
San Francisco, United States Active
Researchers
- Principal investigator: Deitchman, Amelia N — University of California, San Francisco
- Study coordinator: Deitchman, Amelia N
Related research
Other NIH-funded projects on the same topics.
-
Sub-second acetylcholine release in the brain for Alzheimer’s dementia
A small, quick stimulations-based study aims to boost a brain chemical called acetylcholine to help people with Alzheimer’s disease by using a targeted brain stimulation approach.
-
Improving HIV-related brain infections by studying how drugs reach the brain
This grant looks at how well drugs reach the brain and spine to treat HIV-related infections like cryptococcal meningitis and TB meningitis in people with AIDS.
-
Transdermal delivery patch for zanamivir to treat influenza in patients
A new skin patch delivers zanamivir to people with flu or at risk of flu, aiming for easier, safer treatment than pills.
-
Chesapeake-Ohio Pharmacokinetics Core supports cancer drug testing
A collaborative core lab helps researchers study how cancer drugs behave in the body to improve clinical trials and patient care.
-
Urine color test to check tuberculosis drug levels in children and adults
This project uses a simple urine color test to see whether children and adults with TB are getting enough of key TB medicines like rifampin.
-
Making brain-targeted protein degraders work for Alzheimer’s related dementia
A research project at UC San Diego aims to develop smarter drug molecules that can cross the brain barrier and selectively remove disease-related proteins linked to Alzheimer’s, with potential benefits for people living with dementia.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.